(Reuters) -Gilead Sciences and the Global Fund to Fight AIDS, Tuberculosis and Malaria said on Wednesday they had finalized ...

Sexual health doesn’t always get the spotlight it deserves. But modern HIV protection platform Mistr PrEP is helping change ...

Gilead announced a deal to get its groundbreaking HIV prevention drug to lower income countries. Notably, the deal does not ...

Lenacapavir offers twice-yearly HIV prevention with near-complete protection in clinical trials. Clinical trials show ...

Gilead Sciences, in partnership with the Global Fund, plans to supply a long-acting HIV prevention drug to low-income ...

Rep. Marjorie Taylor Greene (R-GA) ranted about how the U.S. sends money to Africa to prevent the spread of HIV, arguing that ...

Global Fund aims for the first shipment to reach at least one African country by year-end. Read more at straitstimes.com.

The FDA has approved a breakthrough preventative treatment for HIV that could change the course of the AIDS epidemic. But ...

A secondary analysis of a large trial shows that exposure to the HIV drug abacavir is linked to an elevated risk for major ...

People living with HIV face unique oral health challenges that require special attention and care. The virus's impact on the ...

Is the cost of research aimed at curing HIV worth it, when HIV can be effectively managed and prevented by existing drugs?

The results expose a striking prevalence of high-risk sexual behaviours. Over one-third of participants (34.0%) disclosed ...